Abstract
Ampakines are a class of putative nootropic drug designed to positively modulate the AMPA receptor and have been investigated as a potential treatment for cognitive disorders such as Alzheimers Disease. Nonetheless, some ampakines such as CX717 have been incompletely characterized in behavioural pharmacological studies. Therefore, in this study, we attempted to further characterize the effects of the ampakine, CX717 (20 mg/kg s.c), on the performance of rats in a 5 choice serial reaction time (5CSRTT) and object recognition memory task, using rats with cognitive deficits caused by bilateral vestibular deafferentation (BVD) as a model. In the 5CSRTT, when the stimulus duration was varied from 5 to 2 sec, the number of incorrect responses was significantly greater for the BVD group compared to sham controls, but significantly less for the CX717 groups, with no significant interaction. With changes in inter-trial interval (ITI), there was a significant effect of surgery/drug and a significant effect of ITI on premature responses, and the BVD group treated with CX717 showed significantly fewer premature responses than the other groups. In the object recognition memory task, CX717 significantly reduced total exploration time and the exploration towards the novel object in both sham and BVD animals. These results suggest that CX717 can reduce the number of incorrect responses in both sham and BVD rats and enhance inhibitory control specifically in BVD rats, in the 5CSRTT. On the other hand, CX717 produced a detrimental effect in the object recognition memory task.
Keywords: Ampakines, nootropic drugs, cognitive dysfunction, vestibular lesions, rats, vestibulo-spinal reflexes, vestibular dysfunction, BVD surgery
Current Alzheimer Research
Title: Effects of the Putative Cognitive-Enhancing Ampakine, CX717, on Attention and Object Recognition Memory
Volume: 8 Issue: 8
Author(s): Yiwen Zheng, Sangeeta Balabhadrapatruni, Chisako Masumura, Cynthia L. Darlington and Paul F. Smith
Affiliation:
Keywords: Ampakines, nootropic drugs, cognitive dysfunction, vestibular lesions, rats, vestibulo-spinal reflexes, vestibular dysfunction, BVD surgery
Abstract: Ampakines are a class of putative nootropic drug designed to positively modulate the AMPA receptor and have been investigated as a potential treatment for cognitive disorders such as Alzheimers Disease. Nonetheless, some ampakines such as CX717 have been incompletely characterized in behavioural pharmacological studies. Therefore, in this study, we attempted to further characterize the effects of the ampakine, CX717 (20 mg/kg s.c), on the performance of rats in a 5 choice serial reaction time (5CSRTT) and object recognition memory task, using rats with cognitive deficits caused by bilateral vestibular deafferentation (BVD) as a model. In the 5CSRTT, when the stimulus duration was varied from 5 to 2 sec, the number of incorrect responses was significantly greater for the BVD group compared to sham controls, but significantly less for the CX717 groups, with no significant interaction. With changes in inter-trial interval (ITI), there was a significant effect of surgery/drug and a significant effect of ITI on premature responses, and the BVD group treated with CX717 showed significantly fewer premature responses than the other groups. In the object recognition memory task, CX717 significantly reduced total exploration time and the exploration towards the novel object in both sham and BVD animals. These results suggest that CX717 can reduce the number of incorrect responses in both sham and BVD rats and enhance inhibitory control specifically in BVD rats, in the 5CSRTT. On the other hand, CX717 produced a detrimental effect in the object recognition memory task.
Export Options
About this article
Cite this article as:
Zheng Yiwen, Balabhadrapatruni Sangeeta, Masumura Chisako, L. Darlington Cynthia and F. Smith Paul, Effects of the Putative Cognitive-Enhancing Ampakine, CX717, on Attention and Object Recognition Memory, Current Alzheimer Research 2011; 8 (8) . https://dx.doi.org/10.2174/156720511798192709
DOI https://dx.doi.org/10.2174/156720511798192709 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Alzheimer's Disease Drug Development
Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Parenting Issues in Mothers with Schizophrenia
Current Women`s Health Reviews Xeno-Cannibalism as an Exacerbation of Self-Cannibalism: A Possible Fruitful Survival Strategy for Cancer Cells
Current Pharmaceutical Design From Small to Powerful: The Fragments Universe and its “Chem-Appeal”
Current Medicinal Chemistry Clinical Trials for Neuroprotection in ALS
CNS & Neurological Disorders - Drug Targets Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors
Current Medicinal Chemistry Laboratory Monitoring of Hematological and Hepatic Parameters in Ambulatory Patients Receiving Alpha-Methyldopa in a Nigerian Tertiary Care Setting
Current Drug Safety Phenothiazine: The Parent Molecule
Current Drug Targets Recent Advances in Apoptosis: THE Role of Hydrazones
Mini-Reviews in Medicinal Chemistry Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry On Therapeutic Drug Monitoring of Thiopurines in Inflammatory Bowel Disease; Pharmacology, Pharmacogenomics, Drug Intolerance and Clinical Relevance
Current Drug Metabolism High Glucose-Mediated Imbalance of Nitric Oxide Synthase and Dimethylarginine Dimethylaminohydrolase Expression in Endothelial Cells
Current Neurovascular Research The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy Transcription Factors as Therapeutic Targets in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) The Role of Probiotics and Prebiotics in Osteolastogenesis and Immune Relevance
Current Medicinal Chemistry Translating Nucleic Acid Amplification Assays to the Microscale: Lab on a Chip for Point-of-Care Molecular Diagnostics
Current Analytical Chemistry PON1 Hypermethylation and PON3 Hypomethylation are Associated with Risk of Cerebral Infarction
Current Neurovascular Research The Efficacy of Cognitive Intervention Programs for Mild Cognitive Impairment: A Systematic Review
Current Alzheimer Research Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets